cholesterol
Early Treatment With Repatha Lowered Incidence of CV Death, Other Events
Long-term treatment with evolocumab in adults with atherosclerosis lowered the incidence of major cardiovascular ...
SEPTEMBER 8, 2022
FDA Approves Leqvio to Lower Cholesterol With Only 2 Doses Per Year
Inclisiran, a first-in-class small interfering RNA, is indicated as an adjunct to diet and maximally tolerated ...
JANUARY 7, 2022
Evinacumab May Help Some Patients With Severe Hypertriglyceridemia
Severe hypertriglyceridemia is a rare disorder that causes extremely high levels of triglycerides, which can lead ...
MAY 17, 2021
New Indication Granted for Repatha for Wider Group of Patients: Adults with CVD
Repatha's indication had been limited to patients with homozygous familial hypercholesterolemia who require ...
DECEMBER 2, 2017
Most Insurers Denying Claims for PCSK9 Inhibitors
PCSK9 inhibitors, such as Repatha and Praluent have been shown to reduce low-density lipoprotein by 60% and ...
NOVEMBER 29, 2017
Amgen Wins Next Step in Patent Dance Over PCSK9 Drugs
Despite the win, the case is long from over; Sanofi and Regeneron plan to appeal.
MARCH 24, 2016
Evolocumab Reduces LDL in Patients With Diabetes
Will PCSK9 drug inhibitors make a difference in how we treat type 2 diabetes?
FEBRUARY 26, 2016
